Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and Immunogenicity of Fluval AB in Adults and Elderly
NCT01649713Phase 4Completed
- Sponsor
- Fluart Innovative Vaccines
- Start
- Aug 2012
- Primary completion
- Sep 2012
- Modality
- Prophylactic Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Fluval AB vaccine in influenza, sponsored by Fluart Innovative Vaccines. Primary endpoint: Assessment of immunogenicity measures in comparison to criteria specified in CPMP/BWP/214/96. Started Aug 2012; status: completed.
02
Drugs
Fluval AB vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01649713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649713.